Thomas Höger
Chief Executive Officer at Apogenix AG
Profile
Thomas Höger is currently the Chief Executive Officer at Apogenix AG since 2009.
Prior to this, he worked as the Head of CNS Research at BASF SE and Knoll AG.
He also worked as an Analyst at DZ Bank AG (Securities).
Thomas Höger active positions
| Companies | Position | Start |
|---|---|---|
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Chief Executive Officer | 2005-10-31 |
Former positions of Thomas Höger
| Companies | Position | End |
|---|---|---|
| DZ Bank AG (Securities) | Analyst-Equity | - |
| BASF SE | Corporate Officer/Principal | - |
Knoll AG
 Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BASF SE | Producer Manufacturing |
| Private companies | 3 |
|---|---|
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Health Technology |
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Health Technology |
| DZ Bank AG (Securities) | Finance |
- Stock Market
- Insiders
- Thomas Höger